Telehealth providers in Alabama

Verified telehealth providers serving Alabama

Telehealth prescribing rules in Alabama

Act 2022-302, codified at Code of Alabama sections 34-24-701 through 34-24-707, replaced Alabama's older special purpose license regime. A physician must hold an Alabama license (or a license through the Interstate Medical Licensure Compact) to treat an Alabama patient by telehealth; there is no out-of-state registration pathway for non-Alabama physicians. A physician may prescribe non-controlled drugs by telehealth without a prior in-person visit if the standard of care is met, but if the same physician or practice group treats the same patient by telehealth more than four times in 12 months for the same unresolved condition, the patient must be seen in person within 12 months or referred to a physician who can see them in person. Controlled substances require a prior in-person visit within 12 months and a real-time encounter. The statute defines telehealth to include both synchronous and asynchronous (store-and-forward) technology, so a non-controlled peptide prescription can lawfully follow an asynchronous evaluation if the physician documents an adequate evaluation; the Board of Medical Examiners implements the act in rule chapter 540-X-24. [6] [7] [13]

Compounded GLP-1 access in Alabama

Compounded semaglutide and tirzepatide are limited to the federal exception for documented patient-specific needs since the FDA shortage declarations ended in 2025, and Alabama is one of the states whose Board of Pharmacy publicly warned pharmacies about semaglutide copies and salt forms. The Board of Medical Examiners has also published fraud alerts about counterfeit Ozempic and unlicensed sellers. [3] [8] [9] [11]

Research use only sellers in Alabama

Selling prescription drugs to Alabama consumers requires a Board of Pharmacy permit, and "research use only" peptides sold for human injection are unapproved new drugs under 21 U.S.C. 331 and 355 regardless of labeling. The Alabama Board of Medical Examiners has warned the public about unlicensed sellers of semaglutide and tirzepatide, and these products are not dispensed by a pharmacist and carry no Alabama consumer protections. In 2026 the Board of Medical Examiners issued a notice that no physician may compound, administer, or dispense a non-FDA-approved or research-grade peptide or delegate that to a CRNP, CNM, or PA, and that physicians must buy all prescription products, drugs, and ingredients from entities permitted by the Alabama State Board of Pharmacy. No research-grade peptide is on any approved CRNP, CNM, or PA formulary, and a patient consent form does not remove the provider's liability. [1] [9] [12] [14]